Research programme: calcitonin gene related peptide receptor antagonists - Bristol-Myers Squibb

Drug Profile

Research programme: calcitonin gene related peptide receptor antagonists - Bristol-Myers Squibb

Alternative Names: BMS-694153; BMS-742413

Latest Information Update: 16 Apr 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Amides; Imidazoles; Indazoles; Piperidines; Quinazolinones
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Migraine

Most Recent Events

  • 11 Apr 2013 Preclinical development is ongoing in USA
  • 06 Sep 2011 Preclinical development is ongoing in USA
  • 21 Aug 2008 Preclinical trials in Migraine in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top